KIMS utilizes ₹1,084 crore of QIP proceeds in Q1FY27
Krishna Institute of Medical Sciences Limited utilized ₹1,084 crore of its ₹1,500 crore QIP in Q1FY27, focusing on debt repayment. CARE Ratings reported no deviations but noted that general corporate purpose funds were commingled with regular business accounts. Unutilized proceeds are held in mutual funds and bank accounts.
*this image is generated using AI for illustrative purposes only.
Krishna Institute of Medical Sciences Limited has utilized ₹1,084 crore of its ₹1,500 crore Qualified Institutional Placement (QIP) proceeds in the quarter ended June 30, 2026. The healthcare company directed the bulk of these funds toward debt reduction, fully repaying ₹910 crore of its own outstanding borrowings and deploying ₹130 crore toward subsidiary debt repayments. This rapid deployment marks significant progress against the placement document’s objective to utilize net proceeds of ₹1,476.45 crore by FY27.
The monitoring agency report, issued by CARE Ratings Limited on August 3, 2026, was reviewed by the Audit Committee of Krishna Institute of Medical Sciences Limited. The filing was submitted pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Regulation 162A(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Pritesh Rath, Associate Director at CARE Ratings, served as the authorized signatory for the report.
Fund Utilization Breakdown
The company allocated its initial utilization primarily to balance sheet optimization. The following table details the deployment of funds across various objects during Q1FY27:
| Object Head | Proposed Amount (₹ Cr) | Utilized in Q1FY27 (₹ Cr) | Unutilized (₹ Cr) |
|---|---|---|---|
| Repayment of KIMS borrowings | 910.00 | 910.00 | Nil |
| Investment in subsidiaries for debt repayment | 215.00 | 130.00 | 85.00 |
| General Corporate Purposes (GCP) | 351.45 | 44.00 | 307.45 |
| Issue Expenses | 23.55 | 2.49 | 21.06 |
| Total | 1,500.00 | 1,086.49 | 413.51 |
Of the ₹130 crore utilized for subsidiary investments, ₹100 crore was deployed for Chalasani Hospitals Pvt Ltd and ₹30 crore for KIMS Hospital Bengaluru Pvt Ltd. The remaining ₹85 crore allocated for subsidiary debt repayment remains unutilized as of June 30, 2026.
General Corporate Purposes and Commingling
For General Corporate Purposes (GCP), the company utilized ₹44 crore. This included ₹22 crore for salaries and consultants, ₹20 crore invested in KIMS Hospital Bengaluru Private Limited, and ₹2 crore in Chalasani Hospitals. CARE Ratings noted a material disclosure regarding fund management: proceeds designated for GCP were transferred to the company’s and subsidiaries’ current accounts. Because these accounts are used for routine business transactions, the monitored proceeds were commingled with regular business funds. The monitoring agency highlighted this structure in its report, noting that while permissible under certain conditions, it reduces the visibility of specific fund tracking compared to segregated accounts.
Deployment of Unutilized Proceeds
As of June 30, 2026, ₹413.51 crore remained unutilized. In line with SEBI regulations allowing temporary investment in creditworthy instruments, the company deployed ₹360 crore into ICICI Prudential Mutual Funds. The remaining balance was held in bank accounts maintained with Kotak Mahindra Bank.
| Instrument / Account | Amount Invested (₹ Cr) | Market Value (₹ Cr) |
|---|---|---|
| Money Market Fund – ICICI Prudential | 250.00 | 250.43 |
| Overnight Fund – ICICI Prudential | 60.00 | 60.13 |
| Liquid Fund – ICICI Prudential | 50.00 | 50.07 |
| Monitoring Agency Account – Kotak Mahindra Bank | 35.75 | - |
| Escrow Account – Kotak Mahindra Bank | 17.76 | - |
| Total | 413.51 | 360.63 |
What the Numbers Show
The immediate and full repayment of ₹910 crore in parent company borrowings signals a strategic priority on deleveraging rather than operational expansion in the first quarter. While this strengthens the balance sheet, the commingling of GCP funds with routine operating accounts introduces a layer of complexity for investors tracking the precise utilization of capital raised. The retention of over ₹400 crore in low-risk liquid instruments suggests the company is maintaining liquidity buffers before committing to further long-term expenditures or subsidiary investments in subsequent quarters.
Historical Stock Returns for Krishna Institute of Medical Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.63% | -2.56% | -3.68% | +3.38% | +3.04% | +198.31% |
How will the significant reduction in interest expenses from the ₹910 crore debt repayment impact KIMS's net profit margins and EBITDA in the upcoming quarters?
What is the specific timeline and strategic rationale for deploying the remaining ₹307.45 crore allocated for General Corporate Purposes, given the current commingling concerns?
Will the commingling of QIP proceeds with routine operating accounts affect future credit ratings or investor confidence, and has CARE Ratings indicated any potential for downgrades based on this structure?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
